KB Investment led a KRW145bn funding round in Orum Therapeutics.

KB Investment, a venture capital company, led a KRW145bn funding round in Orum Therapeutics, a clinical-stage biotech company, with participation from IMM Investment, Woori Venture Partners, Stassets Investment, Weiss Asset Management, Korea Investment Partners, DSC Investment, Company K Partners, AON Investment and DAYLI Partners. “Our mission is to deliver degrader-antibody conjugate therapeutics that apply powerful degrader payloads with antibody-targeted precision to improve the treatment of cancer and other serious diseases. This investment supports the next stage of our growth as we prepare to advance our next therapeutic programs towards clinical evaluation, develop additional novel payloads, and continue to build platforms that can generate differentiated drug candidates across oncology and beyond. We appreciate the confidence of both new and existing investors who share our commitment to delivering meaningful innovation for patients,” Sung Joo (SJ) Lee, Orum Founder and CEO.